Related Experiment Video
Updated: Feb 4, 2026

Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
Published on: May 1, 2019
Pembrolizumab for the treatment of gastric cancer
Suneel D Kamath1, Aparna Kalyan1,2, Al B Benson1,3
1a Division of Hematology/Oncology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.
Introduction:
Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.
Related Concept Videos
Treatment Resistant Cancers
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Gastric Emptying
Gastric Phase of Digestion
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cancer

